One Step at a Time — Clinical Evidence that KRAS Is Indeed Druggable - nejm.org

This article has no abstract; the first 100 words appear below.

Overall survival among patients with advanced-stage KRAS^G12C non–small-cell lung cancer (NSCLC) or colorectal cancer is approximately 1 to 2 years; this startling statistic has fueled nearly four decades of research dedicated to the search for a KRAS-targeted drug.^1,2 Because RAS has picomolar affinity for guanosine triphosphate (GTP) and intracellular GTP concentrations are exceedingly high, early strategies to find compounds that preferentially bind to the RAS–GTP pocket failed. Other strategies have attempted to interfere with RAS activation by preventing its membrane localization or by inhibiting downstream kinase signaling, but these also failed because of resistance stemming from compensatory signaling. Renewed interest . . .

Let's block ads! (Why?)

"time" - Google News
September 20, 2020 at 07:25PM
https://ift.tt/2FOo8Vb

One Step at a Time — Clinical Evidence that KRAS Is Indeed Druggable - nejm.org
"time" - Google News
https://ift.tt/3f5iuuC
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update

Bagikan Berita Ini